Trial Profile
Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 Sep 2018 Status changed from active, no longer recruiting to discontinued.
- 22 Nov 2017 Planned primary completion date changed from 30 Jun 2019 to 31 Jul 2018.
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.